Muthukumaran Jayachandran

Dr. Muthukumaran Jayachandran

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
MJMuthukumaran Jayachandran
Muthukumaran Jayachandran
SQShen Qu
Shen Qu

Verified
Journal Article
Open access
PDF file
KGKumar Ganesan
Kumar Ganesan
MJMuthukumaran Jayachandran
Muthukumaran Jayachandran
Baojun XuBaojun Xu
Baojun Xu
Colorectal cancer (CRC) is a fatal disease caused by the uncontrolled propagation and endurance of atypical colon cells. A person’s lifestyle and eating pattern have significant impacts on the CRC in a positive and/or negative way. Diet-derived phytochemicals modulate the microbiome as well as targeting colon cancer stem cells (CSCs) that are found to offer significant protective effects against CRC, which were organized in an appropriate spot on the paper. All information on dietary phytochemicals, gut microbiome, CSCs, and their influence on CRC were accessed from the various databases and electronic search engines. The effectiveness of CRC can be reduced using various dietary phytochemicals or modulating microbiome that reduces or inverses the progression of a tumor as well as CSCs, which could be a promising and efficient way to reduce the burden of CRC. Phytochemicals with modulation of gut microbiome continue to be auspicious investigations in CRC through noticeable anti-tumorigenic effects and goals to CSCs, which provides new openings for cancer inhibition and treatment.

1 November 2021 in Food Research International
Verified
Journal Article
Closed access
XLXunhan Li
Xunhan Li
MJMuthukumaran Jayachandran
Muthukumaran Jayachandran
Baojun XuBaojun Xu
Baojun Xu

1 January 2020 in International Journal of Medicinal Mushrooms
Verified
Journal Article
Closed access
TZTongze Zhang
Tongze Zhang
MJMuthukumaran Jayachandran
Muthukumaran Jayachandran
KGKumar Ganesan
Kumar Ganesan
Baojun XuBaojun Xu
Baojun Xu
Black truffle mushroom, Tuber melanosporum, is effective in treating various symptoms associated with diabetes mellitus such as hyperglycemia, oxidative stress, and hyperlipidemia and is used as traditional medicine. The aim of our study is to elucidate the antidiabetic potential of T. melanosporum. Male albino Wistar rats were administered a single dose of STZ (40 mg/kg b.w.) to induce mild diabetes mellitus (DM). After the confirmation of hyperglycemia, rats were treated with three different doses of truffle extract (TE) (200, 400, and 600 mg/kg b.w.) for the duration of 45 days. The various tissues were collected at the end of the study. The levels of glucose, oral glucose tolerance test, insulin, hexokinase, glucose 6 phosphatase, and fructose-1,6-bisphosphatase, and regulation of insulin signaling genes were quantified. The results showed that STZ- induced rats have a higher blood glucose level and a lower insulin level compared with the control groups and TE treated groups. Results also reveal that STZ suppressed the expressions of insulin signaling genes in diabetic rats and TE treatment resulted in a positive regulation of the insulin signaling pathway. The results of TE are similar to the results attained in glibenclamide (GB) group rats. Overall, the study provides scientific evidence for the medicinal properties of black truffle; future clinical studies can warrant a potential antidiabetic drug in the form of diet.

1 January 2026 in Italian Journal of Food Science
Verified
Journal Article
Open access
MJMuthukumaran Jayachandran
Muthukumaran Jayachandran
JLJia Liu
Jia Liu
SQShen Qu
Shen Qu
Dietary polysaccharides are effective in mitigating hyperglycemia, insulin resistance, and improving the condition of people with type 2 diabetes mellitus (T2DM). Our investigation explored the changes in the normal microbiome that occur upon high-fat diet feeding and how dietary Dendrobium officinale polysaccharides (DOP) can benefit the treatment of T2DM by mitigating gut microbial dysbiosis. In addition, we have evaluated the changes in lipid metabolism in T2DM mice. Results suggest that HFD feeding (8 weeks) and streptozotocin (120 mg/kg b.w) result in insulin resistance, hyperlipidemia, and gut microbial dysbiosis associated with T2DM. Treatment with DOP results in improved glucose and insulin tolerance, as well as a better plasma and tissue lipid profile. In addition, histopathological and molecular changes support the biochemical observations. Results of gut microbiome studies based on 16S rRNA sequencing suggest that DOP plays a role in improving the population of beneficial bacterial species. In summary, DOP attenuated hyperlipidemia by regulating gut microbial dysbiosis in T2DM.